Roche's Vabysmo Gains Reimbursement in China, Eyes Expansion in Asia
核心洞察
Roche's Vabysmo will be included in China's National Reimbursement Drug List (NRDL) from 2025 to 2026, covering three ophthalmic indications.
This NRDL listing is expected to significantly enhance Vabysmo's accessibility and market penetration within China.
Roche also announced positive interim results for Vabysmo in treating PCV (搜索), potentially broadening its application in Asia.
Roche's Vabysmo, a prominent ophthalmic drug, is set to be included in China's National Reimbursement Drug List (NRDL) from 2025 to 2026, a move that promises to bolster its presence in the Asian market. This inclusion encompasses three key indications, marking a significant milestone for the drug's accessibility within China.
The announcement, made on November 28, signals a major step forward for Roche in making Vabysmo available to a broader patient population in China. The NRDL listing ensures that the drug will be covered by national health insurance, substantially reducing the financial burden on patients.
In addition to the NRDL listing, Roche has reported positive interim results for Vabysmo in the treatment of polypoidal choroidal vasculopathy (搜索) (PCV (搜索)). These findings could pave the way for expanded use of Vabysmo across Asia, addressing a critical unmet need in the region.